Procoagulant activity in gynaecological cancer patients; The effect of surgery and chemotherapy

Thrombosis Research

Volumn 139, Issue , 2016, Pages 135-141

  Abu Saadeh, F ^a   Langhe, R ^a   Galvin, D M ^a   O Toole, S A ^a   O'Donnell, D M ^a   Gleeson, N ^a   Norris, L A ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Anti neoplastic agents; Low molecular weight heparin; Ovarian neoplasms; Thrombin; Venous thromboembolism

Indexed keywords

BIOLOGICAL MARKER; PROCOAGULANT; THROMBIN; THROMBOMODULIN; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ARTICLE; ASSAY; BLOOD CLOTTING; CALIBRATED AUTOMATED THROMBOGRAM; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURGERY; CLEAR CELL CARCINOMA; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FEMALE GENITAL TRACT CANCER; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; LIMIT OF DETECTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MICROPARTICLE ASSAY; MIDDLE AGED; OVARY CARCINOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; ADJUVANT CHEMOTHERAPY; AGED; BLOOD; BLOOD CLOTTING TEST; COMPLICATION; DRUG EFFECTS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; MEMBRANE MICROPARTICLE; METABOLISM; OVARIAN NEOPLASMS; OVARY;

AGED; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CELL-DERIVED MICROPARTICLES; CHEMOTHERAPY, ADJUVANT; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; OVARY; THROMBIN; VENOUS THROMBOEMBOLISM;

EID: 84960085860     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2016.01.027     Document Type: Article

References (32)

1. L.R. Duska, L. Garrett, M. Henretta, J.S. Ferriss, L. Lee, and N. Horowitz When 'never-events' occur despite adherence to clinical guidelines: The case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes Gynecol. Oncol. 116 2010 374 377 10.1016/j.ygyno.2009.10.069
2. M.S. Rasmussen, L.N. Jorgensen, P. Wille-Jorgensen, J.D. Nielsen, A. Horn, A.C. Mohn, L. Somod, and B. Olsen Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: A multicenter randomized open-label study J. Thromb. Haemost. 4 2006 2384 2390 10.1111/j.1538-7836.2006.02153.x
3. M.K. Gould, D.A. Garcia, S.M. Wren, P.J. Karanicolas, J.I. Arcelus, J.A. Heit, and C.M. Samama Prevention of VTE in nonorthopedic surgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e227S e277S 10.1378/chest.11-2297
4. M.N. Levine, G. Raskob, R.J. Beyth, C. Kearon, and S. Schulman Hemorrhagic complications of anticoagulant treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 287S 310S 10.1378/chest.126.3-suppl.287S
5. L.L. Swystun, L.Y. Shin, S. Beaudin, and P.C. Liaw Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytes J. Thromb. Haemost. 7 2009 619 626 10.1111/j.1538-7836.2009.03300.x
6. J. Woodley-Cook, L.Y. Shin, L. Swystun, S. Caruso, S. Beaudin, and P.C. Liaw Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway Mol. Cancer Ther. 5 2006 3303 3311 10.1158/1535-7163.mct-06-0154
7. C. Ay, and I. Pabinger Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients Thromb. Res. 129 Suppl. 1 2012 S6 S9 10.1016/s0049-3848(12)70008-7
8. F.A. Saadeh, L. Norris, S. O'Toole, B.M. Mohamed, R. Langhe, J. O'Leary, and N. Gleeson Tumour expresion of tissue factor and tissue factor pathway inhbitor in ovarian cancer-relationship with venous thrombosis risk Thromb. Res. 2013
9. G.M. Thomas, A. Brill, S. Mezouar, L. Crescence, M. Gallant, C. Dubois, and D.D. Wagner Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice J. Thromb. Haemost. 13 2015 1310 1319 10.1111/jth.13002
10. M.E. Tesselaar, F.P. Romijn, I.K. Van Der Linden, F.A. Prins, R.M. Bertina, and S. Osanto Microparticle-associated tissue factor activity: A link between cancer and thrombosis? J. Thromb. Haemost. 5 2007 520 527 10.1111/j.1538-7836.2007.02369.x
11. J. Thaler, C. Ay, N. Mackman, R.M. Bertina, A. Kaider, C. Marosi, N.S. Key, D.A. Barcel, W. Scheithauer, G. Kornek, C. Zielinski, and I. Pabinger Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients J. Thromb. Haemost. 10 2012 1363 1370 10.1111/j.1538-7836.2012.04754.x
12. J.I. Zwicker, H.A. Liebman, K.A. Bauer, T. Caughey, F. Campigotto, R. Rosovsky, S. Mantha, C.M. Kessler, J. Eneman, V. Raghavan, H.J. Lenz, A. Bullock, E. Buchbinder, D. Neuberg, and B. Furie Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: A randomized-controlled phase II trial (the Microtec study) Br. J. Haematol. 160 2013 530 537 10.1111/bjh.12163
13. C. Ay, D. Dunkler, R. Simanek, J. Thaler, S. Koder, C. Marosi, C. Zielinski, and I. Pabinger Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: Results from the Vienna Cancer and Thrombosis Study J. Clin. Oncol. 29 2011 2099 2103 10.1200/jco.2010.32.8294
14. A. Tripodi, C. Legnani, V. Chantarangkul, B. Cosmi, G. Palareti, and P.M. Mannucci High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism J. Thromb. Haemost. 6 2008 1327 1333 10.1111/j.1538-7836.2008.03018.x
15. M.N. Gionis, C.V. Ioannou, A.N. Katsamouris, P. Katonis, K. Balalis, K. Sfyridaki, I. Elalamy, and G.T. Gerotziafas The study of the thrombin generation mechanism and the effect of low molecular weight heparin as thromboprophylaxis in patients undergoing total knee and hip replacement Thromb. Res. 132 2013 685 691 10.1016/j.thromres.2013.09.037
16. A. Rosenkranz, M. Hiden, B. Leschnik, E.-C. Weiss, D. Schlembach, U. Lang, S. Gallistl, and W. Muntean Calibrated automated thrombin generation in normal uncomplicated pregnancy J. Thromb. Haemost. 99 2008 331 337
17. G.D. Aletti, S.C. Dowdy, K.C. Podratz, and W.A. Cliby Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer Am. J. Obstet. Gynecol. 197 676 2007 e1 e7 10.1016/j.ajog.2007.10.495
18. A.A. Khorana Cancer and coagulation Am. J. Hematol. 87 Suppl. 1 2012 S82 S87 10.1002/ajh.23143
19. K.R. Machlus, E.A. Colby, J.R. Wu, G.G. Koch, N.S. Key, and A.S. Wolberg Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram Thromb. Haemost. 102 2009 936 944 10.1160/th09-03-0180
20. Y.N. Man, Y.N. Wang, J. Hao, X. Liu, C. Liu, C. Zhu, and X.Z. Wu Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism Int. J. Gynecol. Cancer 2014 10.1097/igc.0000000000000303
21. J. Cuff, K. Salari, N. Clarke, G.E. Esheba, A.D. Forster, S. Huang, R.B. West, J.P. Higgins, T.A. Longacre, and J.R. Pollack Integrative bioinformatics links HNF1B with clear cell carcinoma and tumor-associated thrombosis PLoS One 8 2013 e74562 10.1371/journal.pone.0074562
22. J.I. Zwicker, H.A. Liebman, D. Neuberg, R. Lacroix, K.A. Bauer, B.C. Furie, and B. Furie Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy Clin. Cancer Res. 15 2009 6830 6840 10.1158/1078-0432.ccr-09-0371
23. A. Amirkhosravi, Gt Bigsby, H. Desai, M. Rivera-Amaya, E. Coll, L. Robles-Carrillo, P. Faust, A. Waters, T. Meyer, E. Reyes, F. Langer, and J.L. Francis Blood clotting activation analysis for preoperative differentiation of benign versus malignant ovarian masses Blood Coagul. Fibrinolysis 24 2013 510 517 10.1097/MBC.0b013e32835e63b7
24. I. Pabinger, J. Thaler, and C. Ay Biomarkers for prediction of venous thromboembolism in cancer Blood 122 2013 2011 2018 10.1182/blood-2013-04-460147
25. D. Bergqvist, G. Agnelli, A.T. Cohen, A. Eldor, P.E. Nilsson, A. Le Moigne-Amrani, and F. Dietrich-Neto Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer N. Engl. J. Med. 346 2002 975 980 10.1056/NEJMoa012385
26. V.V. Kakkar, J.L. Balibrea, J. Martinez-Gonzalez, and P. Prandoni Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: The CANBESURE randomized study J. Thromb. Haemost. 8 2010 1223 1229 10.1111/j.1538-7836.2010.03892.x
27. F. Abu Saadeh, L. Norris, S. O'Toole, and N. Gleeson Assessing risk and mortality of venous thromboembolism in ovarian cancer patients Int. J. Gynecol. Cancer 22 2012 E246
28. J.A. Heit, M.D. Silverstein, D.N. Mohr, T.M. Petterson, W.M. O'Fallon, and L.J. Melton 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study Arch. Intern. Med. 160 2000 809 815
29. T.C. Haddad, and E.W. Greeno Chemotherapy-induced thrombosis Thromb. Res. 118 2006 555 568 10.1016/j.thromres.2005.10.015
30. M. Roselli, P. Ferroni, S. Riondino, S. Mariotti, A. Laudisi, M. Vergati, F. Cavaliere, R. Palmirotta, and F. Guadagni Impact of chemotherapy on activated protein C-dependent thrombin generation-association with VTE occurrence Int. J. Cancer 133 2013 1253 1258 10.1002/ijc.28104
31. J.S. Rogers II, A.J. Murgo, J.A. Fontana, and P.C. Raich Chemotherapy for breast cancer decreases plasma protein C and protein S J. Clin. Oncol. 6 1988 276 281
32. S.D. Mukherjee, L.L. Swystun, N. Mackman, J.G. Wang, G. Pond, M.N. Levine, and P.C. Liaw Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients Pathophysiol. Haemost. Thromb. 37 2010 88 97 10.1159/000324166